Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28772041 | 0.81 | L3MBTL1 (0.42) | PKMMEN1KMT2AL3MBTL1HTT | |
| SCHEMBL3749548 | 0.80 | METAP1 (0.43) | PKMMEN1KMT2AL3MBTL1HTT | |
| SCHEMBL27979962 | 0.77 | L3MBTL1 (0.39) | PKMMEN1KMT2AL3MBTL1HTT | |
| SCHEMBL3559527 | 0.74 | — | — | |
| SCHEMBL28662185 | 0.74 | ALDH1A1 (0.47) | PKMKMT2AL3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL27852103 | 0.74 | ALDH1A1 (0.43) | PKMMEN1KMT2AL3MBTL1HTT | |
| SCHEMBL27478065 | 0.74 | ALDH1A1 (0.43) | PKMMEN1KMT2AL3MBTL1HTT | |
| SCHEMBL7101570 | 0.73 | PKM (0.39) | PKMMEN1KMT2AL3MBTL1HTT | |
| SCHEMBL13234062 | 0.73 | CYP3A4 (0.45) | PKML3MBTL1ALDH1A1 | |
| SCHEMBL27815518 | 0.73 | ALDH1A1 (0.39) | PKMMEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679370-A | Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals | GRUENENTHAL GMBH | 2010-03-24 | — | — | CN | claimed |
| EP-3512602-B1 | INHIBITORS OF HEAT SHOCK FACTORS (HSF) AND USES THEREOF | HSF PHARMACEUTICALS (CH) | 2024-03-27 | — | — | EP | disclosed |
| CN-117460730-A | Pyrido [4,3-D ] pyrimidine compounds capable of inhibiting KRAS muteins | 莱德克斯制药公共有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-116867779-A | KRAS inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-11597708-B2 | Inhibitors of heat shock factors and uses thereof | HSF PHARMACEUTICALS SA (CH) | 2023-03-07 | — | — | US | disclosed |
| CN-109563120-B | alpha-D-galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20210221778-A1 | Inhibitors of heat shock factors and uses thereof | HSF PHARMACEUTICALS SA (CH) | 2021-07-22 | — | — | US | disclosed |
| EP-3512602-A2 | INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF | HSF Pharmaceuticals (CH) | 2019-07-24 | — | — | EP | disclosed |
| CN-109689647-A | The compound that bicyclic heteroaryl replaces | 百时美施贵宝公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-107108653-B | Pyrazolothiazole compound and medicine | 日本新药株式会社 | 2019-04-09 | — | — | CN | disclosed |
| CN-102307622-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2012-01-04 | — | — | CN | disclosed |
| CN-102143957-A | Benzimidazoles and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2011-08-03 | — | — | CN | disclosed |
| CN-102131805-A | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2011-07-20 | — | — | CN | disclosed |
| CN-102083438-A | Quenolines and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2011-06-01 | — | — | CN | disclosed |
| CN-102066384-A | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO | 2011-05-18 | — | — | CN | disclosed |
| CN-102046628-A | Alpha helix mimetics and methods relating thereto | PRISM BIOLAB CORP | 2011-05-04 | — | — | CN | disclosed |
| CN-101925300-A | Novel compounds as cannabinoid receptor ligands and uses thereof | ABBOTT LAB | 2010-12-22 | — | — | CN | disclosed |
| CN-101765585-A | Antibacterial agent | ACHAOGEN INC | 2010-06-30 | — | — | CN | disclosed |
| CN-101679370-A | Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals | GRUENENTHAL GMBH | 2010-03-24 | — | — | CN | disclosed |
| CN-101421265-A | Thiazole compounds as protein kinase b (pkb) inhibitors | AMGEN INC (US) | 2009-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597708-B2 | Inhibitors of heat shock factors and uses thereof | HSF1, HSP90AB2P, HSP90AB1 | PKM 3069/4885MEN1 4586/4885KMT2A 3452/4885 |
| US-20210221778-A1 | Inhibitors of heat shock factors and uses thereof | HSF1, HSP90AB2P, HSP90AB1 | PKM 3069/4885MEN1 4586/4885KMT2A 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.